Living Well With Brain Cancer: A Group Program to Support Whole-Person Health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study is designed to determine if a newly developed group self-management program is feasible to run and whether it can improve behavioral health outcomes compared with a control group not in a group setting. Participants are adults 18 and older with malignant brain tumors living in the United States, enrolled with a treating provider, and not currently in hospice or receiving psychiatric treatment for a serious mental illness. The intervention consists of group self-management sessions and educational materials, with outcomes assessed against a control condition. The study is led by the University of Colorado, Denver, with collaboration from University Hospitals Cleveland Medical Center, the U.S. Army Medical Research and Development Command, and Case Western Reserve University, and sites in Colorado and Ohio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Currently living in the United States
* Aged 18 years or older
* Confirmed diagnosis of a malignant brain tumor including diffuse gliomas, World Health Organization (WHO) grades II, III, and IV (either by directly sharing their pathology report or confirmation from their prescribing treating provider)
* Treating prescribing provider who follows regularly with participant

Exclusion Criteria:

* \<1 month since initial diagnosis and/or \<1 month since surgical resection
* Enrollment in hospice
* Significant physical or cognitive disabilities that prohibit involvement using our clinician's judgement as a self-management expert, with consultation with personal clinician if needed
* Currently receiving psychiatric treatment for a serious mental illness (e.g., schizophrenia)
* Not able to communicate in English at a conversational level

Where it's running

• University of Colorado Anschutz
  Aurora, Colorado, United States Recruiting
• University Hospitals Cleveland Medical Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Bethany M Kwan, PhD, MSPH — University of Colorado, Denver
• Study coordinator: Research Services Professional
• Email: lwbc@cuanschutz.edu
• Phone: 303-724-1723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pilot test of an active surveillance approach for brain metastases during CNS-penetrant systemic therapy

  A small observational study tests whether an active surveillance plan for newly progressing brain metastases during CNS-penetrant systemic therapy is safe for patients.

  Recruiting University of California, Irvine · Orange, California · NCT07827001

• Precision radiotherapy guided by molecular MRI (APT imaging)

  This project will test whether a special MRI scan called amide proton transfer (APT) imaging can better identify the most aggressive areas of glioblastoma to guide radiotherapy in adults.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07512154

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Fluorescent-labeled nivolumab (Nivo800) imaging for high-grade glioma surgery

  This trial tests whether a near-infrared fluorescent version of the immunotherapy drug nivolumab can be given before planned surgery to visualize drug distribution in adults with suspected high-grade glioma.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07210632

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.